TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06332755: Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Sponsor: LG Chem · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 76 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06332755 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06332755 Rescue Dossier →